Anti-diabetic Medication Comprehensive Study by Type (Insulin (Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin), Drug class (Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione)), Application (Prevent and Treatment Diabetes, Obesity Treatment, Cardiovascular Protection, Others), Route of Administration (Insulin Syringe/ Insulin Pen, Insulin Pump, Intravenous Infusion, Oral, Others), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2026

Report Objectives / Segmentation Covered

• Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
• Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]

• Prevent and Treatment Diabetes
• Obesity Treatment
• Cardiovascular Protection
• Others

• Insulin Syringe/ Insulin Pen
• Insulin Pump
• Intravenous Infusion
• Oral
• Others

• Pediatric
• Adult
• Geriatric

• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • Italy
  • United Kingdom
  • Netherlands
  • Rest of Europe
• MEA
  • Middle East
  • Africa
• North America
  • United States
  • Canada
  • Mexico

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Dynamics
  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Rising Prevalence of Chronic Diseases like Diabetes across the Globe
    • 3.2.2. Growing Prevalence of Lifestyle-Induced Disorders such as Obesity
  • 3.3. Market Challenges
    • 3.3.1. Safety Issues Pertaining to Some Diabetic Drugs
  • 3.4. Market Trends
    • 3.4.1. Increasing Adoption of Oral Antidiabetic Drugs
• 4. Market Factor Analysis
  • 4.1. Porters Five Forces
  • 4.2. Supply/Value Chain
  • 4.3. PESTEL analysis
  • 4.4. Market Entropy
  • 4.5. Patent/Trademark Analysis
• 5. Global Anti-diabetic Medication, by Type, Application, Route of Administration, End User and Region (value, volume and price ) (2015-2020)
  • 5.1. Introduction
  • 5.2. Global Anti-diabetic Medication (Value)
    • 5.2.1. Global Anti-diabetic Medication by: Type (Value)
      • 5.2.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
      • 5.2.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
    • 5.2.2. Global Anti-diabetic Medication by: Application (Value)
      • 5.2.2.1. Prevent and Treatment Diabetes
      • 5.2.2.2. Obesity Treatment
      • 5.2.2.3. Cardiovascular Protection
      • 5.2.2.4. Others
    • 5.2.3. Global Anti-diabetic Medication by: Route of Administration (Value)
      • 5.2.3.1. Insulin Syringe/ Insulin Pen
      • 5.2.3.2. Insulin Pump
      • 5.2.3.3. Intravenous Infusion
      • 5.2.3.4. Oral
      • 5.2.3.5. Others
    • 5.2.4. Global Anti-diabetic Medication by: End User (Value)
      • 5.2.4.1. Pediatric
      • 5.2.4.2. Adult
      • 5.2.4.3. Geriatric
    • 5.2.5. Global Anti-diabetic Medication Region
      • 5.2.5.1. South America
        • 5.2.5.1.1. Brazil
        • 5.2.5.1.2. Argentina
        • 5.2.5.1.3. Rest of South America
      • 5.2.5.2. Asia Pacific
        • 5.2.5.2.1. China
        • 5.2.5.2.2. Japan
        • 5.2.5.2.3. India
        • 5.2.5.2.4. South Korea
        • 5.2.5.2.5. Taiwan
        • 5.2.5.2.6. Australia
        • 5.2.5.2.7. Rest of Asia-Pacific
      • 5.2.5.3. Europe
        • 5.2.5.3.1. Germany
        • 5.2.5.3.2. France
        • 5.2.5.3.3. Italy
        • 5.2.5.3.4. United Kingdom
        • 5.2.5.3.5. Netherlands
        • 5.2.5.3.6. Rest of Europe
      • 5.2.5.4. MEA
        • 5.2.5.4.1. Middle East
        • 5.2.5.4.2. Africa
      • 5.2.5.5. North America
        • 5.2.5.5.1. United States
        • 5.2.5.5.2. Canada
        • 5.2.5.5.3. Mexico
  • 5.3. Global Anti-diabetic Medication (Volume)
    • 5.3.1. Global Anti-diabetic Medication by: Type (Volume)
      • 5.3.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
      • 5.3.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
    • 5.3.2. Global Anti-diabetic Medication by: Application (Volume)
      • 5.3.2.1. Prevent and Treatment Diabetes
      • 5.3.2.2. Obesity Treatment
      • 5.3.2.3. Cardiovascular Protection
      • 5.3.2.4. Others
    • 5.3.3. Global Anti-diabetic Medication by: Route of Administration (Volume)
      • 5.3.3.1. Insulin Syringe/ Insulin Pen
      • 5.3.3.2. Insulin Pump
      • 5.3.3.3. Intravenous Infusion
      • 5.3.3.4. Oral
      • 5.3.3.5. Others
    • 5.3.4. Global Anti-diabetic Medication by: End User (Volume)
      • 5.3.4.1. Pediatric
      • 5.3.4.2. Adult
      • 5.3.4.3. Geriatric
    • 5.3.5. Global Anti-diabetic Medication Region
      • 5.3.5.1. South America
        • 5.3.5.1.1. Brazil
        • 5.3.5.1.2. Argentina
        • 5.3.5.1.3. Rest of South America
      • 5.3.5.2. Asia Pacific
        • 5.3.5.2.1. China
        • 5.3.5.2.2. Japan
        • 5.3.5.2.3. India
        • 5.3.5.2.4. South Korea
        • 5.3.5.2.5. Taiwan
        • 5.3.5.2.6. Australia
        • 5.3.5.2.7. Rest of Asia-Pacific
      • 5.3.5.3. Europe
        • 5.3.5.3.1. Germany
        • 5.3.5.3.2. France
        • 5.3.5.3.3. Italy
        • 5.3.5.3.4. United Kingdom
        • 5.3.5.3.5. Netherlands
        • 5.3.5.3.6. Rest of Europe
      • 5.3.5.4. MEA
        • 5.3.5.4.1. Middle East
        • 5.3.5.4.2. Africa
      • 5.3.5.5. North America
        • 5.3.5.5.1. United States
        • 5.3.5.5.2. Canada
        • 5.3.5.5.3. Mexico
  • 5.4. Global Anti-diabetic Medication (Price)
    • 5.4.1. Global Anti-diabetic Medication by: Type (Price)
• 6. Anti-diabetic Medication: Manufacturers/Players Analysis
  • 6.1. Competitive Landscape
    • 6.1.1. Market Share Analysis
      • 6.1.1.1. Top 3
      • 6.1.1.2. Top 5
  • 6.2. Peer Group Analysis (2020)
  • 6.3. BCG Matrix
  • 6.4. Company Profile
    • 6.4.1. AstraZeneca plc (United Kingdom)
      • 6.4.1.1. Business Overview
      • 6.4.1.2. Products/Services Offerings
      • 6.4.1.3. Financial Analysis
      • 6.4.1.4. SWOT Analysis
    • 6.4.2. Bayer AG (Germany)
      • 6.4.2.1. Business Overview
      • 6.4.2.2. Products/Services Offerings
      • 6.4.2.3. Financial Analysis
      • 6.4.2.4. SWOT Analysis
    • 6.4.3. C.H. Boehringer Sohn AG & Ko. KG (Germany)
      • 6.4.3.1. Business Overview
      • 6.4.3.2. Products/Services Offerings
      • 6.4.3.3. Financial Analysis
      • 6.4.3.4. SWOT Analysis
    • 6.4.4. Bristol-Myers Squibb (United States)
      • 6.4.4.1. Business Overview
      • 6.4.4.2. Products/Services Offerings
      • 6.4.4.3. Financial Analysis
      • 6.4.4.4. SWOT Analysis
    • 6.4.5. Eli Lilly (United States)
      • 6.4.5.1. Business Overview
      • 6.4.5.2. Products/Services Offerings
      • 6.4.5.3. Financial Analysis
      • 6.4.5.4. SWOT Analysis
    • 6.4.6. Halozyme Therapeutics (United States)
      • 6.4.6.1. Business Overview
      • 6.4.6.2. Products/Services Offerings
      • 6.4.6.3. Financial Analysis
      • 6.4.6.4. SWOT Analysis
    • 6.4.7. Johnson & Johnson (United States)
      • 6.4.7.1. Business Overview
      • 6.4.7.2. Products/Services Offerings
      • 6.4.7.3. Financial Analysis
      • 6.4.7.4. SWOT Analysis
    • 6.4.8. Merck & Co. Inc. (United States)
      • 6.4.8.1. Business Overview
      • 6.4.8.2. Products/Services Offerings
      • 6.4.8.3. Financial Analysis
      • 6.4.8.4. SWOT Analysis
    • 6.4.9. Novartis AG (Switzerland)
      • 6.4.9.1. Business Overview
      • 6.4.9.2. Products/Services Offerings
      • 6.4.9.3. Financial Analysis
      • 6.4.9.4. SWOT Analysis
    • 6.4.10. Pfizer Inc. (United States)
      • 6.4.10.1. Business Overview
      • 6.4.10.2. Products/Services Offerings
      • 6.4.10.3. Financial Analysis
      • 6.4.10.4. SWOT Analysis
• 7. Global Anti-diabetic Medication Sale, by Type, Application, Route of Administration, End User and Region (value, volume and price ) (2021-2026)
  • 7.1. Introduction
  • 7.2. Global Anti-diabetic Medication (Value)
    • 7.2.1. Global Anti-diabetic Medication by: Type (Value)
      • 7.2.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
      • 7.2.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
    • 7.2.2. Global Anti-diabetic Medication by: Application (Value)
      • 7.2.2.1. Prevent and Treatment Diabetes
      • 7.2.2.2. Obesity Treatment
      • 7.2.2.3. Cardiovascular Protection
      • 7.2.2.4. Others
    • 7.2.3. Global Anti-diabetic Medication by: Route of Administration (Value)
      • 7.2.3.1. Insulin Syringe/ Insulin Pen
      • 7.2.3.2. Insulin Pump
      • 7.2.3.3. Intravenous Infusion
      • 7.2.3.4. Oral
      • 7.2.3.5. Others
    • 7.2.4. Global Anti-diabetic Medication by: End User (Value)
      • 7.2.4.1. Pediatric
      • 7.2.4.2. Adult
      • 7.2.4.3. Geriatric
    • 7.2.5. Global Anti-diabetic Medication Region
      • 7.2.5.1. South America
        • 7.2.5.1.1. Brazil
        • 7.2.5.1.2. Argentina
        • 7.2.5.1.3. Rest of South America
      • 7.2.5.2. Asia Pacific
        • 7.2.5.2.1. China
        • 7.2.5.2.2. Japan
        • 7.2.5.2.3. India
        • 7.2.5.2.4. South Korea
        • 7.2.5.2.5. Taiwan
        • 7.2.5.2.6. Australia
        • 7.2.5.2.7. Rest of Asia-Pacific
      • 7.2.5.3. Europe
        • 7.2.5.3.1. Germany
        • 7.2.5.3.2. France
        • 7.2.5.3.3. Italy
        • 7.2.5.3.4. United Kingdom
        • 7.2.5.3.5. Netherlands
        • 7.2.5.3.6. Rest of Europe
      • 7.2.5.4. MEA
        • 7.2.5.4.1. Middle East
        • 7.2.5.4.2. Africa
      • 7.2.5.5. North America
        • 7.2.5.5.1. United States
        • 7.2.5.5.2. Canada
        • 7.2.5.5.3. Mexico
  • 7.3. Global Anti-diabetic Medication (Volume)
    • 7.3.1. Global Anti-diabetic Medication by: Type (Volume)
      • 7.3.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
      • 7.3.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
    • 7.3.2. Global Anti-diabetic Medication by: Application (Volume)
      • 7.3.2.1. Prevent and Treatment Diabetes
      • 7.3.2.2. Obesity Treatment
      • 7.3.2.3. Cardiovascular Protection
      • 7.3.2.4. Others
    • 7.3.3. Global Anti-diabetic Medication by: Route of Administration (Volume)
      • 7.3.3.1. Insulin Syringe/ Insulin Pen
      • 7.3.3.2. Insulin Pump
      • 7.3.3.3. Intravenous Infusion
      • 7.3.3.4. Oral
      • 7.3.3.5. Others
    • 7.3.4. Global Anti-diabetic Medication by: End User (Volume)
      • 7.3.4.1. Pediatric
      • 7.3.4.2. Adult
      • 7.3.4.3. Geriatric
    • 7.3.5. Global Anti-diabetic Medication Region
      • 7.3.5.1. South America
        • 7.3.5.1.1. Brazil
        • 7.3.5.1.2. Argentina
        • 7.3.5.1.3. Rest of South America
      • 7.3.5.2. Asia Pacific
        • 7.3.5.2.1. China
        • 7.3.5.2.2. Japan
        • 7.3.5.2.3. India
        • 7.3.5.2.4. South Korea
        • 7.3.5.2.5. Taiwan
        • 7.3.5.2.6. Australia
        • 7.3.5.2.7. Rest of Asia-Pacific
      • 7.3.5.3. Europe
        • 7.3.5.3.1. Germany
        • 7.3.5.3.2. France
        • 7.3.5.3.3. Italy
        • 7.3.5.3.4. United Kingdom
        • 7.3.5.3.5. Netherlands
        • 7.3.5.3.6. Rest of Europe
      • 7.3.5.4. MEA
        • 7.3.5.4.1. Middle East
        • 7.3.5.4.2. Africa
      • 7.3.5.5. North America
        • 7.3.5.5.1. United States
        • 7.3.5.5.2. Canada
        • 7.3.5.5.3. Mexico
  • 7.4. Global Anti-diabetic Medication (Price)
    • 7.4.1. Global Anti-diabetic Medication by: Type (Price)
• 8. Appendix
  • 8.1. Acronyms
• 9. Methodology and Data Source
  • 9.1. Methodology/Research Approach
    • 9.1.1. Research Programs/Design
    • 9.1.2. Market Size Estimation
    • 9.1.3. Market Breakdown and Data Triangulation
  • 9.2. Data Source
    • 9.2.1. Secondary Sources
    • 9.2.2. Primary Sources
  • 9.3. Disclaimer

• Table 1. Anti-diabetic Medication: by Type(USD Million)
• Table 2. Anti-diabetic Medication Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region USD Million (2015-2020)
• Table 3. Anti-diabetic Medication Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region USD Million (2015-2020)
• Table 4. Anti-diabetic Medication: by Application(USD Million)
• Table 5. Anti-diabetic Medication Prevent and Treatment Diabetes , by Region USD Million (2015-2020)
• Table 6. Anti-diabetic Medication Obesity Treatment , by Region USD Million (2015-2020)
• Table 7. Anti-diabetic Medication Cardiovascular Protection , by Region USD Million (2015-2020)
• Table 8. Anti-diabetic Medication Others , by Region USD Million (2015-2020)
• Table 9. Anti-diabetic Medication: by Route of Administration(USD Million)
• Table 10. Anti-diabetic Medication Insulin Syringe/ Insulin Pen , by Region USD Million (2015-2020)
• Table 11. Anti-diabetic Medication Insulin Pump , by Region USD Million (2015-2020)
• Table 12. Anti-diabetic Medication Intravenous Infusion , by Region USD Million (2015-2020)
• Table 13. Anti-diabetic Medication Oral , by Region USD Million (2015-2020)
• Table 14. Anti-diabetic Medication Others , by Region USD Million (2015-2020)
• Table 15. Anti-diabetic Medication: by End User(USD Million)
• Table 16. Anti-diabetic Medication Pediatric , by Region USD Million (2015-2020)
• Table 17. Anti-diabetic Medication Adult , by Region USD Million (2015-2020)
• Table 18. Anti-diabetic Medication Geriatric , by Region USD Million (2015-2020)
• Table 19. South America Anti-diabetic Medication, by Country USD Million (2015-2020)
• Table 20. South America Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 21. South America Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 22. South America Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 23. South America Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 24. Brazil Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 25. Brazil Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 26. Brazil Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 27. Brazil Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 28. Argentina Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 29. Argentina Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 30. Argentina Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 31. Argentina Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 32. Rest of South America Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 33. Rest of South America Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 34. Rest of South America Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 35. Rest of South America Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 36. Asia Pacific Anti-diabetic Medication, by Country USD Million (2015-2020)
• Table 37. Asia Pacific Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 38. Asia Pacific Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 39. Asia Pacific Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 40. Asia Pacific Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 41. China Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 42. China Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 43. China Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 44. China Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 45. Japan Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 46. Japan Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 47. Japan Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 48. Japan Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 49. India Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 50. India Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 51. India Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 52. India Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 53. South Korea Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 54. South Korea Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 55. South Korea Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 56. South Korea Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 57. Taiwan Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 58. Taiwan Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 59. Taiwan Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 60. Taiwan Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 61. Australia Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 62. Australia Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 63. Australia Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 64. Australia Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 65. Rest of Asia-Pacific Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 66. Rest of Asia-Pacific Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 67. Rest of Asia-Pacific Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 68. Rest of Asia-Pacific Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 69. Europe Anti-diabetic Medication, by Country USD Million (2015-2020)
• Table 70. Europe Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 71. Europe Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 72. Europe Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 73. Europe Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 74. Germany Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 75. Germany Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 76. Germany Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 77. Germany Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 78. France Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 79. France Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 80. France Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 81. France Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 82. Italy Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 83. Italy Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 84. Italy Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 85. Italy Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 86. United Kingdom Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 87. United Kingdom Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 88. United Kingdom Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 89. United Kingdom Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 90. Netherlands Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 91. Netherlands Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 92. Netherlands Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 93. Netherlands Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 94. Rest of Europe Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 95. Rest of Europe Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 96. Rest of Europe Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 97. Rest of Europe Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 98. MEA Anti-diabetic Medication, by Country USD Million (2015-2020)
• Table 99. MEA Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 100. MEA Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 101. MEA Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 102. MEA Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 103. Middle East Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 104. Middle East Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 105. Middle East Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 106. Middle East Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 107. Africa Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 108. Africa Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 109. Africa Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 110. Africa Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 111. North America Anti-diabetic Medication, by Country USD Million (2015-2020)
• Table 112. North America Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 113. North America Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 114. North America Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 115. North America Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 116. United States Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 117. United States Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 118. United States Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 119. United States Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 120. Canada Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 121. Canada Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 122. Canada Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 123. Canada Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 124. Mexico Anti-diabetic Medication, by Type USD Million (2015-2020)
• Table 125. Mexico Anti-diabetic Medication, by Application USD Million (2015-2020)
• Table 126. Mexico Anti-diabetic Medication, by Route of Administration USD Million (2015-2020)
• Table 127. Mexico Anti-diabetic Medication, by End User USD Million (2015-2020)
• Table 128. Anti-diabetic Medication Sales: by Type(KG)
• Table 129. Anti-diabetic Medication Sales Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region KG (2015-2020)
• Table 130. Anti-diabetic Medication Sales Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region KG (2015-2020)
• Table 131. Anti-diabetic Medication Sales: by Application(KG)
• Table 132. Anti-diabetic Medication Sales Prevent and Treatment Diabetes , by Region KG (2015-2020)
• Table 133. Anti-diabetic Medication Sales Obesity Treatment , by Region KG (2015-2020)
• Table 134. Anti-diabetic Medication Sales Cardiovascular Protection , by Region KG (2015-2020)
• Table 135. Anti-diabetic Medication Sales Others , by Region KG (2015-2020)
• Table 136. Anti-diabetic Medication Sales: by Route of Administration(KG)
• Table 137. Anti-diabetic Medication Sales Insulin Syringe/ Insulin Pen , by Region KG (2015-2020)
• Table 138. Anti-diabetic Medication Sales Insulin Pump , by Region KG (2015-2020)
• Table 139. Anti-diabetic Medication Sales Intravenous Infusion , by Region KG (2015-2020)
• Table 140. Anti-diabetic Medication Sales Oral , by Region KG (2015-2020)
• Table 141. Anti-diabetic Medication Sales Others , by Region KG (2015-2020)
• Table 142. Anti-diabetic Medication Sales: by End User(KG)
• Table 143. Anti-diabetic Medication Sales Pediatric , by Region KG (2015-2020)
• Table 144. Anti-diabetic Medication Sales Adult , by Region KG (2015-2020)
• Table 145. Anti-diabetic Medication Sales Geriatric , by Region KG (2015-2020)
• Table 146. South America Anti-diabetic Medication Sales, by Country KG (2015-2020)
• Table 147. South America Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 148. South America Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 149. South America Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 150. South America Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 151. Brazil Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 152. Brazil Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 153. Brazil Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 154. Brazil Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 155. Argentina Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 156. Argentina Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 157. Argentina Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 158. Argentina Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 159. Rest of South America Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 160. Rest of South America Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 161. Rest of South America Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 162. Rest of South America Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 163. Asia Pacific Anti-diabetic Medication Sales, by Country KG (2015-2020)
• Table 164. Asia Pacific Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 165. Asia Pacific Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 166. Asia Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 167. Asia Pacific Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 168. China Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 169. China Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 170. China Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 171. China Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 172. Japan Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 173. Japan Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 174. Japan Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 175. Japan Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 176. India Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 177. India Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 178. India Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 179. India Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 180. South Korea Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 181. South Korea Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 182. South Korea Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 183. South Korea Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 184. Taiwan Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 185. Taiwan Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 186. Taiwan Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 187. Taiwan Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 188. Australia Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 189. Australia Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 190. Australia Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 191. Australia Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 192. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 193. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 194. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 195. Rest of Asia-Pacific Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 196. Europe Anti-diabetic Medication Sales, by Country KG (2015-2020)
• Table 197. Europe Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 198. Europe Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 199. Europe Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 200. Europe Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 201. Germany Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 202. Germany Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 203. Germany Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 204. Germany Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 205. France Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 206. France Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 207. France Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 208. France Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 209. Italy Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 210. Italy Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 211. Italy Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 212. Italy Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 213. United Kingdom Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 214. United Kingdom Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 215. United Kingdom Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 216. United Kingdom Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 217. Netherlands Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 218. Netherlands Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 219. Netherlands Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 220. Netherlands Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 221. Rest of Europe Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 222. Rest of Europe Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 223. Rest of Europe Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 224. Rest of Europe Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 225. MEA Anti-diabetic Medication Sales, by Country KG (2015-2020)
• Table 226. MEA Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 227. MEA Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 228. MEA Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 229. MEA Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 230. Middle East Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 231. Middle East Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 232. Middle East Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 233. Middle East Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 234. Africa Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 235. Africa Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 236. Africa Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 237. Africa Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 238. North America Anti-diabetic Medication Sales, by Country KG (2015-2020)
• Table 239. North America Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 240. North America Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 241. North America Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 242. North America Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 243. United States Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 244. United States Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 245. United States Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 246. United States Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 247. Canada Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 248. Canada Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 249. Canada Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 250. Canada Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 251. Mexico Anti-diabetic Medication Sales, by Type KG (2015-2020)
• Table 252. Mexico Anti-diabetic Medication Sales, by Application KG (2015-2020)
• Table 253. Mexico Anti-diabetic Medication Sales, by Route of Administration KG (2015-2020)
• Table 254. Mexico Anti-diabetic Medication Sales, by End User KG (2015-2020)
• Table 255. Anti-diabetic Medication: by Type(USD/Units)
• Table 256. Company Basic Information, Sales Area and Its Competitors
• Table 257. Company Basic Information, Sales Area and Its Competitors
• Table 258. Company Basic Information, Sales Area and Its Competitors
• Table 259. Company Basic Information, Sales Area and Its Competitors
• Table 260. Company Basic Information, Sales Area and Its Competitors
• Table 261. Company Basic Information, Sales Area and Its Competitors
• Table 262. Company Basic Information, Sales Area and Its Competitors
• Table 263. Company Basic Information, Sales Area and Its Competitors
• Table 264. Company Basic Information, Sales Area and Its Competitors
• Table 265. Company Basic Information, Sales Area and Its Competitors
• Table 266. Anti-diabetic Medication: by Type(USD Million)
• Table 267. Anti-diabetic Medication Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region USD Million (2021-2026)
• Table 268. Anti-diabetic Medication Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region USD Million (2021-2026)
• Table 269. Anti-diabetic Medication: by Application(USD Million)
• Table 270. Anti-diabetic Medication Prevent and Treatment Diabetes , by Region USD Million (2021-2026)
• Table 271. Anti-diabetic Medication Obesity Treatment , by Region USD Million (2021-2026)
• Table 272. Anti-diabetic Medication Cardiovascular Protection , by Region USD Million (2021-2026)
• Table 273. Anti-diabetic Medication Others , by Region USD Million (2021-2026)
• Table 274. Anti-diabetic Medication: by Route of Administration(USD Million)
• Table 275. Anti-diabetic Medication Insulin Syringe/ Insulin Pen , by Region USD Million (2021-2026)
• Table 276. Anti-diabetic Medication Insulin Pump , by Region USD Million (2021-2026)
• Table 277. Anti-diabetic Medication Intravenous Infusion , by Region USD Million (2021-2026)
• Table 278. Anti-diabetic Medication Oral , by Region USD Million (2021-2026)
• Table 279. Anti-diabetic Medication Others , by Region USD Million (2021-2026)
• Table 280. Anti-diabetic Medication: by End User(USD Million)
• Table 281. Anti-diabetic Medication Pediatric , by Region USD Million (2021-2026)
• Table 282. Anti-diabetic Medication Adult , by Region USD Million (2021-2026)
• Table 283. Anti-diabetic Medication Geriatric , by Region USD Million (2021-2026)
• Table 284. South America Anti-diabetic Medication, by Country USD Million (2021-2026)
• Table 285. South America Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 286. South America Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 287. South America Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 288. South America Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 289. Brazil Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 290. Brazil Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 291. Brazil Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 292. Brazil Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 293. Argentina Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 294. Argentina Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 295. Argentina Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 296. Argentina Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 297. Rest of South America Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 298. Rest of South America Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 299. Rest of South America Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 300. Rest of South America Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 301. Asia Pacific Anti-diabetic Medication, by Country USD Million (2021-2026)
• Table 302. Asia Pacific Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 303. Asia Pacific Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 304. Asia Pacific Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 305. Asia Pacific Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 306. China Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 307. China Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 308. China Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 309. China Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 310. Japan Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 311. Japan Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 312. Japan Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 313. Japan Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 314. India Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 315. India Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 316. India Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 317. India Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 318. South Korea Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 319. South Korea Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 320. South Korea Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 321. South Korea Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 322. Taiwan Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 323. Taiwan Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 324. Taiwan Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 325. Taiwan Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 326. Australia Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 327. Australia Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 328. Australia Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 329. Australia Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 330. Rest of Asia-Pacific Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 331. Rest of Asia-Pacific Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 332. Rest of Asia-Pacific Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 333. Rest of Asia-Pacific Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 334. Europe Anti-diabetic Medication, by Country USD Million (2021-2026)
• Table 335. Europe Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 336. Europe Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 337. Europe Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 338. Europe Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 339. Germany Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 340. Germany Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 341. Germany Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 342. Germany Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 343. France Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 344. France Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 345. France Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 346. France Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 347. Italy Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 348. Italy Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 349. Italy Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 350. Italy Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 351. United Kingdom Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 352. United Kingdom Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 353. United Kingdom Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 354. United Kingdom Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 355. Netherlands Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 356. Netherlands Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 357. Netherlands Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 358. Netherlands Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 359. Rest of Europe Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 360. Rest of Europe Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 361. Rest of Europe Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 362. Rest of Europe Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 363. MEA Anti-diabetic Medication, by Country USD Million (2021-2026)
• Table 364. MEA Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 365. MEA Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 366. MEA Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 367. MEA Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 368. Middle East Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 369. Middle East Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 370. Middle East Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 371. Middle East Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 372. Africa Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 373. Africa Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 374. Africa Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 375. Africa Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 376. North America Anti-diabetic Medication, by Country USD Million (2021-2026)
• Table 377. North America Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 378. North America Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 379. North America Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 380. North America Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 381. United States Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 382. United States Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 383. United States Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 384. United States Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 385. Canada Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 386. Canada Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 387. Canada Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 388. Canada Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 389. Mexico Anti-diabetic Medication, by Type USD Million (2021-2026)
• Table 390. Mexico Anti-diabetic Medication, by Application USD Million (2021-2026)
• Table 391. Mexico Anti-diabetic Medication, by Route of Administration USD Million (2021-2026)
• Table 392. Mexico Anti-diabetic Medication, by End User USD Million (2021-2026)
• Table 393. Anti-diabetic Medication Sales: by Type(KG)
• Table 394. Anti-diabetic Medication Sales Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region KG (2021-2026)
• Table 395. Anti-diabetic Medication Sales Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region KG (2021-2026)
• Table 396. Anti-diabetic Medication Sales: by Application(KG)
• Table 397. Anti-diabetic Medication Sales Prevent and Treatment Diabetes , by Region KG (2021-2026)
• Table 398. Anti-diabetic Medication Sales Obesity Treatment , by Region KG (2021-2026)
• Table 399. Anti-diabetic Medication Sales Cardiovascular Protection , by Region KG (2021-2026)
• Table 400. Anti-diabetic Medication Sales Others , by Region KG (2021-2026)
• Table 401. Anti-diabetic Medication Sales: by Route of Administration(KG)
• Table 402. Anti-diabetic Medication Sales Insulin Syringe/ Insulin Pen , by Region KG (2021-2026)
• Table 403. Anti-diabetic Medication Sales Insulin Pump , by Region KG (2021-2026)
• Table 404. Anti-diabetic Medication Sales Intravenous Infusion , by Region KG (2021-2026)
• Table 405. Anti-diabetic Medication Sales Oral , by Region KG (2021-2026)
• Table 406. Anti-diabetic Medication Sales Others , by Region KG (2021-2026)
• Table 407. Anti-diabetic Medication Sales: by End User(KG)
• Table 408. Anti-diabetic Medication Sales Pediatric , by Region KG (2021-2026)
• Table 409. Anti-diabetic Medication Sales Adult , by Region KG (2021-2026)
• Table 410. Anti-diabetic Medication Sales Geriatric , by Region KG (2021-2026)
• Table 411. South America Anti-diabetic Medication Sales, by Country KG (2021-2026)
• Table 412. South America Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 413. South America Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 414. South America Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 415. South America Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 416. Brazil Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 417. Brazil Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 418. Brazil Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 419. Brazil Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 420. Argentina Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 421. Argentina Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 422. Argentina Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 423. Argentina Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 424. Rest of South America Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 425. Rest of South America Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 426. Rest of South America Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 427. Rest of South America Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 428. Asia Pacific Anti-diabetic Medication Sales, by Country KG (2021-2026)
• Table 429. Asia Pacific Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 430. Asia Pacific Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 431. Asia Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 432. Asia Pacific Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 433. China Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 434. China Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 435. China Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 436. China Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 437. Japan Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 438. Japan Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 439. Japan Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 440. Japan Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 441. India Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 442. India Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 443. India Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 444. India Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 445. South Korea Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 446. South Korea Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 447. South Korea Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 448. South Korea Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 449. Taiwan Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 450. Taiwan Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 451. Taiwan Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 452. Taiwan Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 453. Australia Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 454. Australia Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 455. Australia Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 456. Australia Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 457. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 458. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 459. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 460. Rest of Asia-Pacific Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 461. Europe Anti-diabetic Medication Sales, by Country KG (2021-2026)
• Table 462. Europe Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 463. Europe Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 464. Europe Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 465. Europe Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 466. Germany Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 467. Germany Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 468. Germany Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 469. Germany Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 470. France Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 471. France Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 472. France Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 473. France Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 474. Italy Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 475. Italy Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 476. Italy Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 477. Italy Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 478. United Kingdom Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 479. United Kingdom Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 480. United Kingdom Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 481. United Kingdom Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 482. Netherlands Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 483. Netherlands Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 484. Netherlands Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 485. Netherlands Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 486. Rest of Europe Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 487. Rest of Europe Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 488. Rest of Europe Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 489. Rest of Europe Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 490. MEA Anti-diabetic Medication Sales, by Country KG (2021-2026)
• Table 491. MEA Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 492. MEA Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 493. MEA Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 494. MEA Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 495. Middle East Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 496. Middle East Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 497. Middle East Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 498. Middle East Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 499. Africa Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 500. Africa Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 501. Africa Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 502. Africa Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 503. North America Anti-diabetic Medication Sales, by Country KG (2021-2026)
• Table 504. North America Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 505. North America Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 506. North America Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 507. North America Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 508. United States Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 509. United States Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 510. United States Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 511. United States Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 512. Canada Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 513. Canada Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 514. Canada Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 515. Canada Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 516. Mexico Anti-diabetic Medication Sales, by Type KG (2021-2026)
• Table 517. Mexico Anti-diabetic Medication Sales, by Application KG (2021-2026)
• Table 518. Mexico Anti-diabetic Medication Sales, by Route of Administration KG (2021-2026)
• Table 519. Mexico Anti-diabetic Medication Sales, by End User KG (2021-2026)
• Table 520. Anti-diabetic Medication: by Type(USD/Units)
• Table 521. Research Programs/Design for This Report
• Table 522. Key Data Information from Secondary Sources
• Table 523. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Anti-diabetic Medication: by Type USD Million (2015-2020)
• Figure 5. Global Anti-diabetic Medication: by Application USD Million (2015-2020)
• Figure 6. Global Anti-diabetic Medication: by Route of Administration USD Million (2015-2020)
• Figure 7. Global Anti-diabetic Medication: by End User USD Million (2015-2020)
• Figure 8. South America Anti-diabetic Medication Share (%), by Country
• Figure 9. Asia Pacific Anti-diabetic Medication Share (%), by Country
• Figure 10. Europe Anti-diabetic Medication Share (%), by Country
• Figure 11. MEA Anti-diabetic Medication Share (%), by Country
• Figure 12. North America Anti-diabetic Medication Share (%), by Country
• Figure 13. Global Anti-diabetic Medication: by Type KG (2015-2020)
• Figure 14. Global Anti-diabetic Medication: by Application KG (2015-2020)
• Figure 15. Global Anti-diabetic Medication: by Route of Administration KG (2015-2020)
• Figure 16. Global Anti-diabetic Medication: by End User KG (2015-2020)
• Figure 17. South America Anti-diabetic Medication Share (%), by Country
• Figure 18. Asia Pacific Anti-diabetic Medication Share (%), by Country
• Figure 19. Europe Anti-diabetic Medication Share (%), by Country
• Figure 20. MEA Anti-diabetic Medication Share (%), by Country
• Figure 21. North America Anti-diabetic Medication Share (%), by Country
• Figure 22. Global Anti-diabetic Medication: by Type USD/Units (2015-2020)
• Figure 23. Global Anti-diabetic Medication share by Players 2020 (%)
• Figure 24. Global Anti-diabetic Medication share by Players (Top 3) 2020(%)
• Figure 25. Global Anti-diabetic Medication share by Players (Top 5) 2020(%)
• Figure 26. BCG Matrix for key Companies
• Figure 27. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
• Figure 28. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
• Figure 29. Bayer AG (Germany) Revenue, Net Income and Gross profit
• Figure 30. Bayer AG (Germany) Revenue: by Geography 2020
• Figure 31. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
• Figure 32. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2020
• Figure 33. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
• Figure 34. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
• Figure 35. Eli Lilly (United States) Revenue, Net Income and Gross profit
• Figure 36. Eli Lilly (United States) Revenue: by Geography 2020
• Figure 37. Halozyme Therapeutics (United States) Revenue, Net Income and Gross profit
• Figure 38. Halozyme Therapeutics (United States) Revenue: by Geography 2020
• Figure 39. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
• Figure 40. Johnson & Johnson (United States) Revenue: by Geography 2020
• Figure 41. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
• Figure 42. Merck & Co. Inc. (United States) Revenue: by Geography 2020
• Figure 43. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
• Figure 44. Novartis AG (Switzerland) Revenue: by Geography 2020
• Figure 45. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
• Figure 46. Pfizer Inc. (United States) Revenue: by Geography 2020
• Figure 47. Global Anti-diabetic Medication: by Type USD Million (2021-2026)
• Figure 48. Global Anti-diabetic Medication: by Application USD Million (2021-2026)
• Figure 49. Global Anti-diabetic Medication: by Route of Administration USD Million (2021-2026)
• Figure 50. Global Anti-diabetic Medication: by End User USD Million (2021-2026)
• Figure 51. South America Anti-diabetic Medication Share (%), by Country
• Figure 52. Asia Pacific Anti-diabetic Medication Share (%), by Country
• Figure 53. Europe Anti-diabetic Medication Share (%), by Country
• Figure 54. MEA Anti-diabetic Medication Share (%), by Country
• Figure 55. North America Anti-diabetic Medication Share (%), by Country
• Figure 56. Global Anti-diabetic Medication: by Type KG (2021-2026)
• Figure 57. Global Anti-diabetic Medication: by Application KG (2021-2026)
• Figure 58. Global Anti-diabetic Medication: by Route of Administration KG (2021-2026)
• Figure 59. Global Anti-diabetic Medication: by End User KG (2021-2026)
• Figure 60. South America Anti-diabetic Medication Share (%), by Country
• Figure 61. Asia Pacific Anti-diabetic Medication Share (%), by Country
• Figure 62. Europe Anti-diabetic Medication Share (%), by Country
• Figure 63. MEA Anti-diabetic Medication Share (%), by Country
• Figure 64. North America Anti-diabetic Medication Share (%), by Country
• Figure 65. Global Anti-diabetic Medication: by Type USD/Units (2021-2026)

• AstraZeneca plc (United Kingdom)
• Bayer AG (Germany)
• C.H. Boehringer Sohn AG & Ko. KG (Germany)
• Bristol-Myers Squibb (United States)
• Eli Lilly (United States)
• Halozyme Therapeutics (United States)
• Johnson & Johnson (United States)
• Merck & Co. Inc. (United States)
• Novartis AG (Switzerland)
• Pfizer Inc. (United States)